Navigation Links
Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium

Two-Day Multiplexing Technology Symposium Brings Together Thought Leaders in Life Sciences and Clinical Diagnostics to Share Ideas and Best Practices

OOSTERHOUT, Netherlands, Sept. 13 /PRNewswire-FirstCall/ -- Luminex Corporation (Nasdaq: LMNX), the world leader in multiplexed solutions, today announced the agenda for Planet xMAP Europe 2007, the company's annual European end-user technology symposium. The two-day event will be held 2-3 October at the Berlage's Exchange in Amsterdam, the Netherlands, and will feature a range of presentations regarding Luminex's flexible xMAP(R) multiplexing technology in clinical diagnostics and life science research applications.

"We are thrilled to welcome xMAP technology end-users back to The Netherlands for our fifth annual Planet xMAP Europe," said Paul C. Ladestein, Director of European Operations for Luminex. "This event will allow scientists, researchers and clinicians to come together to share best practices and ideas not only about xMAP technology, but about the broader role that multiplexing technology is playing to improve research and enhance the quality of patient care."

Planet xMAP Europe 2007 will feature two days of presentations and workshops. Day One, Tuesday, 2 October, will concentrate on xMAP-based clinical diagnostics applications and include the following presentations:

-- Dr. John C. Carrano, Vice President, Research and Development Luminex Corporation (USA) - "xMAPing the Future: A Vision of Innovative Products and Dominant Solutions"

-- Dr. Susan J. Wong, Diagnostic Immunology Laboratory, Wadsworth Center NYSDOH (USA) - "Comparison of AtheNA Multi-Lyte Bb Microsphere Immunoassay to Two-Tier Serology for Laboratory Confirmation of Lyme Disease"

-- Dr. Mario J. Marcon, Director of Clinical/Molecular Microbiology, Virology, & Immunoserology, Department of Laboratory Medicine Children's Hospital, Columbus, OH (USA) - "Evaluation of the Plexus Epstein Barr Virus Panels in a children's Hospital Setting"

-- Professor Kai Zacharowski, M.D., Ph.D., Chair of Cardiovascular Anesthesia & Critical Care, Bristol Royal Infirmary (United Kingdom) - "Cytokines - From Head to Toe"

-- Dr. Diana Pauly, Center for Biological Safety, Microbial Toxins, Robert Koch-Institute (Germany) - "Simultaneous Detection of Bacterial and Plant Toxins Using a Multiplex Magnetic Bead Assay"

-- Dr. Gary T. Brice, United States Navy Medical Research Unit, Department of Immunology (Indonesia) - "Etiology of Respiratory Viral Pathogens in Suspect H5N1 Samples in Indonesia"

Day Two of Planet xMAP Europe 2007, Wednesday, 3 October, will focus on xMAP-based life science research applications and feature the following presentations:

-- Dr. Marion Lanteri, Postdoctoral Fellow, Immunology - "Cytokine Signature of Early Viral Infections"

-- Professor Thomas Herget, Ph.D., Director PLS R&D/New Technology Evaluation, Merck KGaA (Germany) - "Safety Biomarkers: Holy Grail of Toxicology"

-- Dr. Jochen Schwenk, KTH - Royal Institute of Technology, Alba Nova University Center, Department of Proteomics (Sweden) - "Multiplexed Approaches within Antibody Proteomics"

-- Dr. Corrado M. Cilio, Cellular Autoimmunity Unit, Department of Clinical Sciences and Pediatrics, Malmo University Hospital (Sweden) - "MicroRNA"

-- Dr. Oliver Poetz, NMI, Natural and Medical Science Institute at the University of Tuebingen (Germany) - "Magnetic Beads Work Better at Night"

-- Dr. Ben van Ommen, TNO Quality Life (The Netherlands), Head of Nutrigenomics and Nutritional Systems Biology Activities - "The Targeted Plasma Proteome in Personalized Health and Nutrition"

For additional information on Planet xMAP Europe 2007 or to register, please visit or contact Jenny Busch (+31-162-408333 (332) or

About Luminex

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP(R) multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP can be obtained at

Luminex Corporate Contact:

Harriss T. Currie

Vice President, Finance and Chief Financial Officer


Luminex Media Contact:

Nicole Cottrill


SOURCE Luminex Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Bacterial RNA Isolation From Infected Eukaryotic Hosts
11. Bacterial RNA Isolation From Infected Eukaryotic Hosts
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report ... detail how a patient who developed lymphedema after being treated for breast cancer benefitted ... change the paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest ... ClinCapture will also be presenting a scientific poster on Disrupting Clinical Trials in ...
Breaking Biology Technology:
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
Breaking Biology News(10 mins):